NCT06534502 - Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

SeizuresSeizures, FocalSeizure, Partial OnsetSeizure Disorder, PartialSeizure, PartialEpilepsies, PartialEpilepsy

Interventions

DRUG

Zonisamide Oral Product

Zonisamide oral suspension

Trial Locations (2)

Wake Forest University School of Medicine, Winston-Salem

Le Bonheur Children's Hospital, Memphis